These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
364 related articles for article (PubMed ID: 15747753)
1. Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration. Hariprasad SM; Mieler WE; Shah GK; Blinder KJ; Apte RS; Holekamp NM; Thomas MA; Chi J; Prince RA Trans Am Ophthalmol Soc; 2004; 102():149-55; discussion 155-7. PubMed ID: 15747753 [TBL] [Abstract][Full Text] [Related]
2. Determination of aqueous and vitreous concentration of moxifloxacin 0.5% after delivery via a dissolvable corneal collagen shield device. Hariprasad SM; Shah GK; Chi J; Prince RA J Cataract Refract Surg; 2005 Nov; 31(11):2142-6. PubMed ID: 16412929 [TBL] [Abstract][Full Text] [Related]
3. Vitreous and aqueous penetration of orally administered moxifloxacin in humans. Vedantham V; Lalitha P; Velpandian T; Ghose S; Mahalakshmi R; Ramasamy K Eye (Lond); 2006 Nov; 20(11):1273-8. PubMed ID: 16200061 [TBL] [Abstract][Full Text] [Related]
4. Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy. Lai WW; Chu KO; Chan KP; Choy KW; Wang CC; Tsang CW; Pang CP Am J Ophthalmol; 2007 Aug; 144(2):315-8. PubMed ID: 17659971 [TBL] [Abstract][Full Text] [Related]
5. Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Hariprasad SM; Blinder KJ; Shah GK; Apte RS; Rosenblatt B; Holekamp NM; Thomas MA; Mieler WF; Chi J; Prince RA Arch Ophthalmol; 2005 Jan; 123(1):39-44. PubMed ID: 15642810 [TBL] [Abstract][Full Text] [Related]
6. The effect of cataract surgery on ocular levels of topical moxifloxacin. Mather R; Stewart JM; Prabriputaloong T; Wong J; McLeod SD Am J Ophthalmol; 2004 Oct; 138(4):554-9. PubMed ID: 15488780 [TBL] [Abstract][Full Text] [Related]
7. Comparison of 2 moxifloxacin regimens for preoperative prophylaxis: prospective randomized triple-masked trial. Part 1: aqueous concentration of moxifloxacin. Vasavada AR; Gajjar D; Raj SM; Vasavada V; Vasavada V J Cataract Refract Surg; 2008 Aug; 34(8):1379-82. PubMed ID: 18655991 [TBL] [Abstract][Full Text] [Related]
8. Vitreous and aqueous penetration of orally administered moxifloxacin in humans. Hariprasad SM; Shah GK; Mieler WF; Feiner L; Blinder KJ; Holekamp NM; Gao H; Prince RA Arch Ophthalmol; 2006 Feb; 124(2):178-82. PubMed ID: 16476886 [TBL] [Abstract][Full Text] [Related]
9. Vitreal penetration of oral and topical moxifloxacin in humans. Fuller JJ; Lott MN; Henson NM; Bhatti AA; Singh H; McGwin G; Marcus DM Am J Ophthalmol; 2007 Feb; 143(2):338-40. PubMed ID: 17258525 [TBL] [Abstract][Full Text] [Related]
10. Vitreous and aqueous penetration of orally and topically administered moxifloxacin. Fukuda M; Shibata N; Osada H; Yamashiro Y; Sasaki H Ophthalmic Res; 2011; 46(3):113-7. PubMed ID: 21325873 [TBL] [Abstract][Full Text] [Related]
12. Clearance of intravitreal moxifloxacin. Iyer MN; He F; Wensel TG; Mieler WF; Benz MS; Holz ER Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):317-9. PubMed ID: 16384979 [TBL] [Abstract][Full Text] [Related]
13. Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. Holland EJ; Lane SS; Kim T; Raizman M; Dunn S Cornea; 2008 Apr; 27(3):314-9. PubMed ID: 18362660 [TBL] [Abstract][Full Text] [Related]
14. Aqueous humor and plasma concentrations of ciprofloxacin and moxifloxacin following topical ocular administration in ophthalmologically normal horses. Clode AB; Davis JL; Salmon J; LaFevers H; Gilger BC Am J Vet Res; 2010 May; 71(5):564-9. PubMed ID: 20433383 [TBL] [Abstract][Full Text] [Related]
15. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Robertson SM; Curtis MA; Schlech BA; Rusinko A; Owen GR; Dembinska O; Liao J; Dahlin DC Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S32-45. PubMed ID: 16257309 [TBL] [Abstract][Full Text] [Related]
16. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. McCulley JP; Caudle D; Aronowicz JD; Shine WE Ophthalmology; 2006 Jun; 113(6):955-9. PubMed ID: 16603244 [TBL] [Abstract][Full Text] [Related]
17. Comparative penetration of moxifloxacin and gatifloxacin in rabbit aqueous humor after topical dosing. Levine JM; Noecker RJ; Lane LC; Herrygers L; Nix D; Snyder RW J Cataract Refract Surg; 2004 Oct; 30(10):2177-82. PubMed ID: 15474833 [TBL] [Abstract][Full Text] [Related]
18. Vitreous penetration of topical moxifloxacin and gatifloxacin in humans. Costello P; Bakri SJ; Beer PM; Singh RJ; Falk NS; Peters GB; Melendez JA Retina; 2006 Feb; 26(2):191-5. PubMed ID: 16467677 [TBL] [Abstract][Full Text] [Related]
19. Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model. Yağci R; Oflu Y; Dinçel A; Kaya E; Yağci S; Bayar B; Duman S; Bozkurt A Eye (Lond); 2007 Jul; 21(7):990-4. PubMed ID: 16732216 [TBL] [Abstract][Full Text] [Related]
20. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Kim DH; Stark WJ; O'Brien TP; Dick JD Ophthalmology; 2005 Nov; 112(11):1992-6. PubMed ID: 16183125 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]